KR-33493 |
| رقم الكتالوجGC19214 |
KR-33493 هو مثبط قوي لموت الخلايا بوساطة Fas (FAF1)
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1021497-97-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
KR-33493 is a potent inhibitor of Fas-mediated cell death (FAF1).
Body weight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups of either sex are found in hematology, serum biochemistry, and urinalysis. In dogs administrated KR-33493 for 2 weeks, red blood cell count (RBC) value in males is significantly higher at the 1000 mg/kg/day dose than that of the control group (i.e., 6.96±0.323 vs. 6.12±0.418). However, the change of RBC is recovered after the end of the administration period. The dose-normalized AUClast is not significantly different between the groups, suggesting that KR-33493 is governed by linear kinetics[1].
References:
[1]. Jeong JW, et al. Subacute toxicity evaluation of KR-33493, FAF1 inhibitor for a new anti-parkinson's disease agent, after oral administration in rats and dogs. Regul Toxicol Pharmacol. 2016 Nov;81:387-396.
Animal experiment: | A total of 93 male and 93 female specific pathogen-free rats (6 weeks of age), and 16 male and 16 female beagle dogs (8 months of age) are used in this study. In a toxicokinetic study, rat blood samples (approximately 0.6 mL) are collected into tubes containing heparin from the lateral tail vein at 0, 0.5, 1, 2, 4, 8, 12, and 24 h after dosing with KR-33493 at doses of 50, 150, and 500 mg/kg/day on Day 1 and Week 4. Dog blood samples (approximately 0.6 mL) are collected into tubes containing EDTA-2K from the cephalic vein at 0, 0.5, 1, 2, 4, 6, 8, and 24 h after dosing at KR-33493 doses of 50, 250, and 1000 mg/kg/day on Day 1 and Week 2. The plasma is separated by centrifugation (approximately 132,000 g, 3 min, 4°C) and stored at approximately -80°C until analysis. The KR-33493 concentration in plasma is quantified[1]. |
References: [1]. Jeong JW, et al. Subacute toxicity evaluation of KR-33493, FAF1 inhibitor for a new anti-parkinson's disease agent, after oral administration in rats and dogs. Regul Toxicol Pharmacol. 2016 Nov;81:387-396. | |
| Cas No. | 1021497-97-1 | SDF | |
| Canonical SMILES | OC(C1=NN(CCC2=CC=CC=C2)C=C1NC(CSC3=CC=C(Br)C=C3)=O)=O | ||
| Formula | C20H18BrN3O3S | M.Wt | 460.34 |
| الذوبان | DMSO : ≥ 31 mg/mL (67.34 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1723 mL | 10.8615 mL | 21.7231 mL |
| 5 mM | 0.4345 mL | 2.1723 mL | 4.3446 mL |
| 10 mM | 0.2172 mL | 1.0862 mL | 2.1723 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *